William Blair started coverage on shares of Cambrex (NYSE:CBM) in a research note published on Tuesday morning, MarketBeat Ratings reports. The brokerage issued an outperform rating on the biotechnology company’s stock. William Blair also issued estimates for Cambrex’s Q4 2017 earnings at $1.09 EPS, FY2017 earnings at $2.96 EPS, FY2018 earnings at $2.95 EPS, FY2019 earnings at $3.13 EPS, FY2020 earnings at $3.32 EPS and FY2021 earnings at $3.61 EPS.
CBM has been the topic of several other reports. Zacks Investment Research raised shares of Cambrex from a strong sell rating to a hold rating in a research report on Monday, January 15th. Craig Hallum reissued a buy rating and issued a $60.00 price objective (down from $70.00) on shares of Cambrex in a research report on Tuesday, October 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. Cambrex currently has an average rating of Hold and a consensus target price of $60.50.
Shares of Cambrex (CBM) traded up $0.30 on Tuesday, hitting $56.30. 304,025 shares of the stock traded hands, compared to its average volume of 240,443. The company has a market capitalization of $1,835.55, a price-to-earnings ratio of 18.77, a PEG ratio of 1.33 and a beta of 2.27. Cambrex has a 52 week low of $42.55 and a 52 week high of $62.95.
Cambrex (NYSE:CBM) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.47 by $0.08. The company had revenue of $112.60 million for the quarter, compared to analyst estimates of $108.44 million. Cambrex had a net margin of 18.79% and a return on equity of 23.42%. The company’s revenue was up 13.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.47 earnings per share. analysts anticipate that Cambrex will post 2.97 earnings per share for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in the stock. Stifel Financial Corp increased its position in Cambrex by 0.8% during the second quarter. Stifel Financial Corp now owns 4,580 shares of the biotechnology company’s stock worth $275,000 after acquiring an additional 37 shares during the period. YorkBridge Wealth Partners LLC increased its position in Cambrex by 5.2% during the second quarter. YorkBridge Wealth Partners LLC now owns 1,971 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 97 shares during the period. PNC Financial Services Group Inc. increased its position in Cambrex by 0.5% during the second quarter. PNC Financial Services Group Inc. now owns 22,178 shares of the biotechnology company’s stock worth $1,325,000 after acquiring an additional 119 shares during the period. Suntrust Banks Inc. increased its position in Cambrex by 2.8% during the second quarter. Suntrust Banks Inc. now owns 7,355 shares of the biotechnology company’s stock worth $439,000 after acquiring an additional 201 shares during the period. Finally, Amalgamated Bank increased its position in Cambrex by 6.1% during the second quarter. Amalgamated Bank now owns 4,473 shares of the biotechnology company’s stock worth $267,000 after acquiring an additional 258 shares during the period.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.